Novel Treatment for Rare Neuroendocrine Diseases with Dr. Nerissa Kreher Tiburio

Published: July 16, 2019, 4:25 p.m.

Dr. Nerissa Kreher, Chief Medical Officer, Tiburio discusses the company's lead asset, TBR-760 as a novel treatment option for patients with non-functioning pituitary adenomas (NFPA), which are rare neuroendocrine tumors located in the pituitary gland.  She also speaks about the challenges facing patients even after surgical or radiation treatments for these pituitary tumors.

@TiburioT

#neuroendocrine  #pituitaryadenoma  #chiefmedicalofficer  #raredisease  #NFPA 

Tiburio Therapeutics

Download the PDF file of the interview here.